Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 5, 2012, Pages 787-792

  Tajima, Hidehiro ^a   Ohta, Tetsuo ^a   Kitagawa, Hirohisa ^a   Okamoto, Koichi ^a   Sakai, Seisho ^a   Makino, Isamu ^a   Kinoshita, Jun ^a   Furukawa, Hiroyuki ^a   Nakamura, Keishi ^a   Hayashi, Hironori ^a   Oyama, Katsunobu ^a   Inokuchi, Masafumi ^a   Nakagawara, Hisatoshi ^a   Fujita, Hideto ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Fushida, Sachio ^a   Tani, Takashi ^a   Fujimura, Takashi ^a   Ikeda, Hiroko ^b   Kitamura, Seiko ^b   more..

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gemcitabine; Neoadjuvant chemotherapy; Pancreatic cancer; S 1

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; TEGAFUR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LEUKOPENIA; LIVER INJURY; LYMPHADENECTOMY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PANCREATIC DUCTAL ADENOCARCINOMA; PILOT STUDY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84858681096     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.482     Document Type: Article

References (30)

1. Ministry of Health, Labour and Welfare: The Dynamic Statistics of the Population in 2005. http//www.mhlw.go.jp/toukei/saikin/hw/jinkou/ kakutei05/hyo7/html (11 June 2009, data last accepted).
2. Ishii H, Furuse J, Boku N, et al: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol doi:10.1093/jjco/hyq011, 2010.
3. Nagakawa T, Kurachi M, Konishi K, et al: Translateral retroperitoneal approach in radical surgery for pancreatic carcinoma. Jpn J Surg 12: 229-233, 1982.
4. Nagakawa T, Nagamori M, Futakami F, et al: Result of extensive surgery for pancreatic carcinoma. Cancer 77: 640-645, 1996.
5. Miwa K, Ohta T, Shimizu K, et al: Augmented regional pancreatoduodenectomy for pancreas head cancer: combined resection of pancreas head and superior mesenteric artery and vein. American College of Surgeons 90th Annual Clinical Congress, Chicago:Isis 190, 2004.
6. Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology. 6th edition. De Vita, Hellman S and Rosenberg SA (eds). Lippincott, Williams and Wilkins, Philadelphia, pp1126-1161, 2001.
7. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007.
8. Klinlenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230: 776-782, 1999.
9. Spitz FR, Abbruzzese JL, Lee JE, et al: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15: 928-937, 1997.
10. Yeo CJ, Abrams RA, Grochow LB, et al: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225: 621-633, 1997.
11. Shirasaka T, Shimamoto Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
12. Tatsumi K, Fukushima M, Shirasaki T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyrimidine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78: 748-755, 1987.
13. Takechi T, Fujioka A, Matssushima E, et al: Enhancement of the antitumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumor cells. Eur J Cancer 38: 1271-1277, 2002.
14. Peters GJ, van Groeningen CJ, Laurensse EJ and Pinedo HM: A compression of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68: 1903-1909, 1991.
15. Takechi T, Nakano K, Uchida J, et al: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39: 205-211, 1997.
16. Nakamura K, Yamaguchi T, Ishihara T, et al: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 92: 2134-2139, 2005.
17. Ueno H, Okusaka T, Ikeda M, et al: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69: 421-427, 2005.
18. Nakamura K, Yamaguchi T, Ishihara T, et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer: 1-5, 2006.
19. Vento P, Mustonen H, Joensuu T, et al: Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol 21: 2945-2951, 2007.
20. Palmer DH, Stocken DD, Hewitt H, et al: A randomized phase 2 trial of neo-adjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14: 2088-2096, 2007.
21. Sato N, Kurashima K, Nagai H, et al: The effect of adjuvant and neoadjuvant chemo (radio) therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg 16: 485-492, 2009.
22. Satoi S, Yanagimoto H, Toyokawa H, et al: Surgical result after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 38: 282-288, 2008.
23. Rauchwerger DR, Firby PS, Hedley DW and Moore MJ: Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075-6079, 2000.
24. Makino I, Kitagawa H, Ohta T, et al: Nerve plexus invasion in pancreatic cancer. Spread patterns on histopathologic and embryological analysis. Pancreas 37: 358-365, 2008.
25. Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127: 1335-1339, 1992.
26. Esposito I, Kleeff J, Bergmann F, et al: Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15: 1651-1660, 2008.
27. Nakahira S, Nakamori S, Tsujie M, et al: Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effect in pancreatic cancer xenografts. Anticancer Res 28: 179-186, 2008.
28. Takai S, Satoi S, Yanagimoto H, et al: Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas 36: 26-32, 2008.
29. Golcher H, Brunner T, Grabenbauer G, et al: Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. EJSO 34: 756-764, 2008.
30. Van Laethem JL, Hammel P, Mornex F, et al: Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012 /FFCD-9203/GERCOR phase II study. J Clin Oncol 28: 4450-4456, 2010.